Andy is currently Professor of Medical Biotechnology, University of Aberdeen, Scotland and Director of the Scottish Biologics Facility. He was founder and CSO of the University spin-out Haptogen Ltd. until it was acquired, in October 2007, by Wyeth Inc. In 2005 he was made the Ernst and Young Plc, UK Science and Technology Entrepreneur of the Year. In 2006 he became a Fellow of the Royal Society of Edinburgh and a Fellow of the Royal Society of Biology in 2012. Andy has been on the Board of the biologics company NovaBiotics Ltd since 2009. NovaBiotics currently has two products in Ph 2 clinical trials, a global licensing deal with Taro Inc and a City funding round by Woodford Investment Management. Andy is a graduate of St Andrew’s University.